List view / Grid view
30 October 2014 | By Eli Lilly and Company
Eli Lilly and Company published details of its long-standing technology transfer program to increase the global supply of medicines for multidrug-resistant tuberculosis (MDR-TB)...
30 October 2014 | By PresseBox
It has become a tradition to recognize pharma innovation at CPhI Worldwide, as CPhI Pharma awards winners driving Pharma's biggest innovations...
29 October 2014 | By Merck
Merck announced today the signature of a memorandum of understanding with Kenya Medical Research Institution (KEMRI) for a scientific partnership aimed at contributing to the country’s social and economic development. The partnership will cover research and development projects, programs and activities focused on malaria and schistosomiasis, as well as related…
29 October 2014 | By GBI Research
The global Non-Hodgkin Lymphoma (NHL) treatment market will increase in value from $5.6 billion in 2013 to $9.2 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 7.4%, says business intelligence provider GBI Research...
29 October 2014 | By Eli Lilly and Company
Eli Lilly and Company (LLY) will participate in the Credit Suisse 2014 Healthcare Conference at the Arizona Biltmore in Phoenix, AZ, on Wednesday, November 12, 2014. Jeffrey Simmons, Senior Vice President and President, Elanco Animal Health, will make a formal presentation at 1:30 p.m. EST...
29 October 2014 | By Sanofi
Sanofi's Board of Directors have decided unanimously to remove Christopher A. Viehbacher as Chief Executive Officer of Sanofi. As a consequence Christopher A. Viehbacher resigned as a director of Sanofi...
28 October 2014 | By Eli Lilly &Company
Eli Lilly and Company LLY, -2.58% issued the following statement in response to a judge's ruling that the punitive damages awarded in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, No. 6:12-cv-00064 be reduced...
28 October 2014 | By Boehringer Ingelheim
Global top 20 pharma company streamlines R&D IT with cross-domain platform...
28 October 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and F-star Alpha Ltd. announced that the companies, together with the F-star Alpha Ltd. shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire F-star Alpha Ltd, and gain worldwide rights to its lead asset FS102...
28 October 2014 | By Distributed by APO (African Press Organization) on behalf of SkyVision Global Networks Ltd
The fund will be used to cover expenses and the needs of Ebola patients and affected families...
28 October 2014 | By Moberg Pharma
Moberg Pharma AB announced that the first patient has been included in a randomized controlled phase ll study with BUPI, a novel topical formulation for the treatment of oral pain...
27 October 2014 | By Imaxio
Imaxio announces that it has been awarded funding of EUR 600,000 (USD 772,000) by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project 'leveraging On t-cell immune resPonse To Improve influenza VACcines'...
27 October 2014 | By Roche
Roche announced that Esbriet® (pirfenidone) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for an update to its European prescribing information, strengthening the efficacy claims and supporting the well-established safety profile based on the additional data from the phase III ASCEND trial...
27 October 2014 | By Genticel
Genticel announces its net cash position and its highlights from the third quarter of 2014...
27 October 2014 | By AB Consulting
The Chief Executive of Valeant, the Canadian based speciality drugmaker recently commented that ‘the pharmaceutical industry is stuck in the 1980’s with big bureaucratic R&D functions that produce little value’...
